At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 272 enrolled
Drug / intervention
TA-7284 Low +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TA-7284 as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating TA-7284 Low, TA-7284 High, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 272 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedAug 2011
Primary CompletionAug 2012
TodayJul 2026
First PostedAug 10, 2011
Enrollment StartJul 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.9 years ago
Interventions
TA-7284 Lowdrug
The patients will receive TA-7284-Low orally for 24 weeks.
TA-7284 Highdrug
The patients will receive TA-7284-High orally for 24 weeks.
Placebodrug
The patients will receive Placebo orally for 24 weeks.